Core Viewpoint - The stock price of Ruimait has increased by 5.18% on November 21, reaching 97.00 CNY per share, with a total market capitalization of 8.691 billion CNY, reflecting a cumulative increase of 11.11% over the past five days [1] Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established on July 27, 2001, and went public on November 1, 2022. The company specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea hypopnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The revenue composition of the company includes: 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Fund Holdings - The Xinda Australia Fund has a significant holding in Ruimait, with the Xinda Small and Medium Cap Mixed A Fund (610004) holding 116,500 shares, accounting for 4.31% of the fund's net value, making it the eighth largest holding [2] - The fund has realized a floating profit of approximately 556,800 CNY today and a total of 1,073,900 CNY during the five-day increase [2] Fund Manager Information - The fund manager of Xinda Small and Medium Cap Mixed A Fund is Zeng Guofu, who has a cumulative tenure of 17 years and 119 days, with a total fund size of 585 million CNY. The best return during his tenure is 109.1%, while the worst is -57.43% [3] - Co-manager Li Diandian has a tenure of 1 year and 38 days, managing a fund size of 525 million CNY, with a best return of 34.07% and a worst return of 12.72% during his tenure [3]
瑞迈特股价涨5.18%，信达澳亚基金旗下1只基金重仓，持有11.65万股浮盈赚取55.68万元